First Manhattan CO Akebia Therapeutics, Inc. Transaction History

First Manhattan CO

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2020 Nov 12, 2020	SELL	$2.39 - $13.08 $2 Million - $10.9 Million	-835,900 Closed	0 $0
Q2 2020 Aug 14, 2020	BUY	$6.67 - $13.58 $5.58 Million - $11.4 Million	835,900 New	835,900 $11.4 Million
Q1 2020 May 06, 2020	SELL	$4.1 - $10.24 $507,989 - $1.27 Million	-123,900 Closed	0 $0
Q3 2019 Nov 13, 2019	BUY	$3.55 - $5.4 $439,845 - $669,060	123,900 New	123,900 $485,000
Q1 2019 Apr 12, 2019	SELL	$5.41 - $8.73 $1.41 Million - $2.27 Million	-260,200 Closed	0 $0
Q4 2018 Jan 30, 2019	SELL	$5.39 - $9.15 $2.92 Million - $4.95 Million	-541,166 Reduced 67.53%	260,200 $1.44 Million
Q3 2018 Oct 15, 2018	BUY	$7.44 - $10.65 $1.76 Million - $2.52 Million	236,300 Added 41.82%	801,366 $7.08 Million
Q4 2017 Jan 22, 2018	SELL	$14.24 - $19.59 $4.95 Million - $6.81 Million	-347,434 Reduced 38.07%	565,066 $8.4 Million
Q3 2017 Oct 25, 2017	BUY	$13.06 - $19.67 $11.9 Million - $17.9 Million	912,500	912,500 $17.9 Million

120

54.8M

291K

179K

Ticker AKBA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 183,848,992
Market Cap $324M
Description
Akebia Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics for patients with kidney diseases. The company's lead product investigational product candidate is vadadustat, an oral therapy, which is in Phase III development for the treatment of anemia due to chronic kidney disease (CKD) ...

Get notified when there are updates to the investment portfolio of First Manhattan CO, based on Form 13F filings with the SEC.

Stay updated on First Manhattan CO with notifications on news.